The Phase II portion is seeking to establish safety and efficacy of the company’s HER2 breast cancer therapy in combination ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

The field of central nervous system (CNS) drug development is awash with activity. And major new centres of research are ...

Q4 2024 Earnings Call Transcript February 20, 2025 Prothena Corporation plc misses on earnings expectations. Reported EPS is ...

Sarah Hubar-Fisher will be Yaqrit's VP of Business Development with particular responsibility for the two medical device assets entering registrational trials in 2025. Her 20 years at Johnson & ...

The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.

CSL Behring KK has gained approval from Japan's MHLW to manufacture and market subcutaneous injection 200mg Andembry pens.

Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.

(formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate ...

The evolution of functional assessments for spinal muscular atrophy (SMA) highlights the challenges of adapting pediatric ...

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.